Paolo Ascierto, MD, of the National Tumor Institute Fondazione G. Pascale, Naples, Italy, discusses the Phase II safety study CheckMate 172 of nivolumab for treating advanced melanoma patients (NCT02156804). He mentions that patients of the study were pre-treated with ipilimumab, and in case of BRAF mutation, were also treated with a BRAF inhibitor. Over 1000 patients were enrolled in the study, and results will be shown regarding the first 300 patients, who have a minimum follow-up of six months. He further highlights that the results that were to be presented are very preliminary results but are interesting as they confirm in terms of safety the data that was published in The Lancet Oncology for the trial of CheckMate 037 (NCT01721746), i.e. the same response rate and safety. The data in the trial in general shows interesting results in select subgroups, such as the patients with a performance status (PS) of 2, patients with brain metastases, or patients with mucosal and uveal melanoma. Finally, he explains that at the moment, data is not available for this cohort, but he hopes that updates will be presented at a future meeting. Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.